Literature DB >> 12363064

The effects of antimalarial drugs on ventricular repolarization.

J E Touze1, P Heno, L Fourcade, J C Deharo, G Thomas, S Bohan, P Paule, P Riviere, E Kouassi, A Buguet.   

Abstract

Cardiotoxicity has become a major concern during treatment with antimalarial drugs. Lengthening of the QTc and severe cardiac arrhythmia have been observed, particularly after treatment with halofantrine for chloroquine-resistant Plasmodium falciparum malaria. The purpose of this prospective study was to evaluate whether antimalarial agents alter dispersion of the QTc and ventricular repolarization dynamicity. Sixty patients with uncomplicated falciparum malaria were randomly allocated in four groups of 15 patients and treated with quinine, mefloquine, artemether, or halofantrine at recommended doses. Patients in treatment groups were compared with a group including 15 healthy controls with no history of malaria and/or febrile illness within the last month. QTc dispersion was measured on surface electrocardiograms. Repolarization dynamicity was analyzed from Holter recordings, which allow automatic beat-to-beat measurement of QT and RR intervals. Plasma drug concentration was determined by reversed-phase high-performance liquid chromatography. No change in QTc dispersion was observed after treatment with quinine, mefloquine, or artemether. Treatment with halofantrine was followed by a significant increase in QTc dispersion at 9 hours (P < 0.0001) and 24 hours (P < 0.01). Assessment of QT heart rate variability by QT/RR nychtohemeral regression slope demonstrated no significant difference between the artemether (mean +/- SEM = 0.170 +/- 0.048), mefloquine (0.145 +/- 0.044), and the control groups (0.172 +/- 0.039). A significant decrease in the Q-eT/RR slope was observed in the quinine group compared with the control and artemether groups (0.135 +/- 0.057; P < 0.04). With halofantrine, a significant increase in the QT/RR regression slope (0.289 +/- 0.118) was observed (P < 0.0002). QTc interval, QT dispersion, and QT regression slope were significantly correlated with halofantrine and quinine plasma concentration. Mefloquine and artemether did not alter ventricular repolarization. Quinine induced a significant decrease in QT/RR slope of the same order of magnitude as those previously observed with quinidine. Both QTc dispersion and QT/RR slope were significantly modified by halofantrine. These repolarization changes were related to a class-III antiarrhythmic drug effect and may explain the occurrence of ventricular arrhythmia and/or sudden deaths reported after halofantrine intake.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12363064     DOI: 10.4269/ajtmh.2002.67.54

Source DB:  PubMed          Journal:  Am J Trop Med Hyg        ISSN: 0002-9637            Impact factor:   2.345


  14 in total

1.  Piperaquine Population Pharmacokinetics and Cardiac Safety in Cambodia.

Authors:  Pattaraporn Vanachayangkul; Chanthap Lon; Michele Spring; Sommethy Sok; Winita Ta-Aksorn; Chanikarn Kodchakorn; Sut-Thang Pann; Soklyda Chann; Mali Ittiverakul; Sabaithip Sriwichai; Nillawan Buathong; Worachet Kuntawunginn; Mary So; Theng Youdaline; Erin Milner; Mariusz Wojnarski; Charlotte Lanteri; Jessica Manning; Satharath Prom; Mark Haigney; Louis Cantilena; David Saunders
Journal:  Antimicrob Agents Chemother       Date:  2017-04-24       Impact factor: 5.191

2.  New fixed-dose artesunate-mefloquine formulation against multidrug-resistant Plasmodium falciparum in adults: a comparative phase IIb safety and pharmacokinetic study with standard-dose nonfixed artesunate plus mefloquine.

Authors:  S Krudsood; S Looareesuwan; N Tangpukdee; P Wilairatana; W Phumratanaprapin; W Leowattana; K Chalermrut; S Ramanathan; V Navaratnam; P Olliaro; M Vaillant; J R Kiechel; W R J Taylor
Journal:  Antimicrob Agents Chemother       Date:  2010-06-14       Impact factor: 5.191

Review 3.  Plasmodium drug targets outside the genetic control of the parasite.

Authors:  David J Sullivan
Journal:  Curr Pharm Des       Date:  2013       Impact factor: 3.116

4.  Primary hypothyroidism with an episode of ventricular tachycardia in a patient with COVID-19: A case report.

Authors:  Pin-Hsu Liao; Yu-Cheng Cheng; Po-Yu Liu; I-Te Lee
Journal:  Medicine (Baltimore)       Date:  2022-06-24       Impact factor: 1.817

5.  Safety evaluation of fixed combination piperaquine plus dihydroartemisinin (Artekin) in Cambodian children and adults with malaria.

Authors:  Harin Karunajeewa; Chiv Lim; Te-Yu Hung; Kenneth F Ilett; Mey Bouth Denis; Doung Socheat; Timothy M E Davis
Journal:  Br J Clin Pharmacol       Date:  2004-01       Impact factor: 4.335

6.  Drug-likeness of linear pentamidine analogues and their impact on the hERG K+ channel - correlation with structural features.

Authors:  Teresa Żołek; Muge Qile; Paweł Kaźmierczak; Meye Bloothooft; Marcel A G van der Heyden; Dorota Maciejewska
Journal:  RSC Adv       Date:  2019-12-02       Impact factor: 3.361

7.  Erythrocyte G protein as a novel target for malarial chemotherapy.

Authors:  Sean C Murphy; Travis Harrison; Heidi E Hamm; Jon W Lomasney; Narla Mohandas; Kasturi Haldar
Journal:  PLoS Med       Date:  2006-12       Impact factor: 11.069

Review 8.  Fatal cardiotoxicity related to halofantrine: a review based on a worldwide safety data base.

Authors:  Olivier Bouchaud; Patrick Imbert; Jean Etienne Touze; Alex N O Dodoo; Martin Danis; Fabrice Legros
Journal:  Malar J       Date:  2009-12-10       Impact factor: 2.979

9.  Summary of recommendations on malaria issues in special hosts.

Authors:  A Boggild; J Brophy; P Charlebois; M Crockett; J Geduld; W Ghesquiere; P McDonald; P Plourde; P Teitelbaum; M Tepper; S Schofield; A McCarthy
Journal:  Can Commun Dis Rep       Date:  2014-05-15

10.  Electrocardiographic study in Ghanaian children with uncomplicated malaria, treated with artesunate-amodiaquine or artemether-lumefantrine.

Authors:  George O Adjei; Collins Oduro-Boatey; Onike P Rodrigues; Lotte C Hoegberg; Michael Alifrangis; Jorgen A Kurtzhals; Bamenla Q Goka
Journal:  Malar J       Date:  2012-12-17       Impact factor: 2.979

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.